Artera

ArteraAI develops multimodal AI tests that read digital pathology images alongside clinical data to estimate a cancer patient's risk and predict benefit from specific treatments. The analysis runs on the standard H&E stained tissue slides that already exist from a biopsy or surgery, so no additional staining or tissue is consumed, and results are typically returned within one to two days. The tests are ordered by oncologists and urologists and used by patients weighing how intensive their treatment should be. The ArteraAI Prostate Test is available for biopsy samples in early stage disease, for tissue after radical prostatectomy, and for metastatic hormone sensitive prostate cancer. The ArteraAI Breast Cancer Test estimates five and ten year distant metastasis risk for early stage breast cancer. The company states that its models were validated on data from large randomized phase III clinical trials and evaluated for consistent performance across racial groups. Testing runs in the company's CAP certified, CLIA laboratory, the organization holds SOC 2 Type II compliance, and clinicians order through an online portal. No list price is published. The Prostate Test is fully reimbursed under Medicare's established payment rate, and many commercial plans cover it subject to copays, coinsurance and deductibles. A financial assistance program offers tiered patient costs of $0, $95, $190 or $285 based on household income and size, and self pay estimates are available from the billing team. The prostate test received FDA De Novo authorization in 2025 after earlier Breakthrough Device Designation, which sets it apart from most AI pathology software that is sold for research use only.